- Coordinator
- Vulkania Labs SL, Spain
- Runs
- 1 July 2026 to 30 June 2028
- Status
- Running
- EU funding
- €499k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101310871
What the project is doing
In the project's own words, from its summary on CORDIS.
PHYTOLOOP is a deep-tech biomanufacturing project by Kanara (Vulkania Labs S.L.) that enables the sustainable, traceable and scalable production of high-value plant-derived Active Pharmaceutical Ingredients (APIs) from endangered and endemic species, starting with the Canary Islands’ unique flora. The project replaces destructive wild harvesting and inefficient agricultural extraction with a modular, AI-assisted in-vitro platform that cultivates plant cells in closed bioreactors under fully controlled, sterile conditions.
The approach integrates AI-driven optimisation, advanced plant biotechnology and automated bioreactors to drastically reduce trial-and-error in media formulation and process control, achieving ≥50 % fewer optimisation cycles, ≥20 % lower production cost and reproducible yields with <10 % batch variability. By maintaining elite, high-yielding cell lines ex-situ, the system ensures perpetual access to valuable APIs while conserving biodiversity.
Over 24 months, PHYTOLOOP will evolve from TRL 4 to TRL 6, delivering a validated 50 L automated pilot line and a regulatory-ready platform for pharmaceutical adoption. The project includes four technical and business objectives:1. Establish stable in-vitro cell lines from at least three endangered endemic species;2. Integrate and automate the full pilot-scale bioprocess;3. Validate market demand through Letters of Intent and an investor-ready data room;4.
Define GMP and industrialisation roadmaps for post-project pilots. Backed by confirmed LOIs from pharma and institutional partners (Adventia Pharma, MOEVE, CSIC, ICIA) and co-funded 30 % by Kanara, PHYTOLOOP anchors a new biodiversity-based bio-industry in the Canary Islands, strengthening EU strategic autonomy in APIs while creating a replicable, nature-positive model of industrial biotechnology.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Vulkania Labs SL | Santa Ursula Santa Cruz De Tenerife | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI